<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04508712</url>
  </required_header>
  <id_info>
    <org_study_id>COVID-19 Prognosis</org_study_id>
    <nct_id>NCT04508712</nct_id>
  </id_info>
  <brief_title>Long-term Outcomes in Patients With COVID-19</brief_title>
  <official_title>Long-term Outcomes in Patients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Long-term outcomes from coronavirus disease 2019 (COVID-19) are currently unknown. This study
      will collect daily living status of survivors of COVID-19.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ongoing pandemic of coronavirus disease 2019 (COVID-19), due to the newly discovered
      severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2), has caused a worldwide increase
      in hospitalization for pneumonia with multi- organ disease. Survival from sepsis is
      associated with increased risk for mortality for at least 2 years. Therefore, substantial
      sequelae including new physical disability, new cognitive impairment and increased
      vulnerability to further health deterioration are likely to be seen in survivors of COVID-19.
      The investigators conduct this study to investigate daily living status of survivors of
      COVID-19 using telephone interview questionnaire including Activity Daily Living(ADL),
      modified Medical Research Council(mMRC),modified Telephone Interview for Cognitive Status
      (TICS-m), Zung Self-rating Depression Scale(SDS), Carcinologic Handicap Index (CHI), and New
      York Heart Association (NYHA) functional class.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 10, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Physical functions</measure>
    <time_frame>4-6 months</time_frame>
    <description>Physical functions will be assessed using Activities of daily living (ADL) scale. Minimum value:0, Maximum value: 100. Higher scores mean a better outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Respiratory function</measure>
    <time_frame>4-6 months</time_frame>
    <description>Respiratory function will be assessed using modified Medical Research Council(mMRC) scale. Minimum value:0, Maximum value: 4. Higher scores mean a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>4-6 months</time_frame>
    <description>Cognitive function will be assessed using modified Telephone Interview for Cognitive Status (TICS-m) scale. Minimum value:0, Maximum value: 50. Higher scores mean a better outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Depression status</measure>
    <time_frame>4-6 months</time_frame>
    <description>Depression status will be assessed using Zung Self-rating Depression Scale(SDS). Minimum value:25, Maximum value: 125. Higher scores mean a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensory functions</measure>
    <time_frame>4-6 months</time_frame>
    <description>Sensory functions will be assessed using Carcinologic Handicap Index (CHI). Minimum value:0, Maximum value: 144. Higher scores mean a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart function</measure>
    <time_frame>4-6 months</time_frame>
    <description>Heart function will be assessed using New York Heart Association (NYHA) functional class. Minimum value:1, Maximum value: 4. Higher scores mean a worse outcome.</description>
  </primary_outcome>
  <enrollment type="Anticipated">900</enrollment>
  <condition>COVID-19</condition>
  <eligibility>
    <study_pop>
      <textblock>
        This study will enroll survivors of COVID-19 aged over 18 years old who had been admitted
        in Leishenshan Hospital for COVID-19 patients in Wuhan, China.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Survivors who had been admitted in Leishenshan Hospital for COVID-19 patients in
             Wuhan, China

        Exclusion Criteria:

          -  Patients who were &lt; 18 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weifeng Yu, MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>Renji Hospital, School of Medicine, Shanghai Jiaotong University, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diansan Su, MD,PhD</last_name>
    <phone>+8618616514088</phone>
    <email>diansansu@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Renji Hospital, Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Pudong</city>
        <state>Shanghai</state>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Diansan Su, MD,PhD</last_name>
      <phone>8618616514088</phone>
      <email>diansansu@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 8, 2020</study_first_submitted>
  <study_first_submitted_qc>August 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2020</study_first_posted>
  <last_update_submitted>August 17, 2020</last_update_submitted>
  <last_update_submitted_qc>August 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>long-term outcomes</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

